55 % Overall Response Rate on the safety extension cohorts of the ISO-CC-005 Phase I/IIa study
GOTHENBURG, Sweden, September 30, 2020 – Isofol Medical AB (publ), (Nasdaq First North Premier Growth Market: ISOFOL), today provided an…
Privacy & Cookies Policy
These cookies are necessary for the website to function properly. These cookies ensure basic functionalities and security features of the website. These cookies do not store any personally identifiable information.